Hemostats Market projected stable 6% CAGR driven by demand from dental and orthopedic surgeries 2030
Global
Hemostats Market valued at $2.7 billion in 2021 and is set to
witness a healthy growth rate of 6% by 2030.Surge in surgical
procedures (related to cardiovascular surgery, general surgery, plastic
surgery, orthopedic surgery, neurosurgery, dentistry, obstetrics, and
gynecology), rising cases of trauma, technological advancements in hemostats,
shrinking blood supply/donor pool in several countries, and growth
opportunities in emerging markets are some of the key factors driving the
market’s growth.
Hemostasis is the body’s natural reaction to an injury that
stops bleeding and repairs the damage. The capability helps in conserving blood
and prevents infection. Hemostats are surgical tools that are used in surgical
procedures to control bleeding.
Discover the more details-Download the PDF brochure :
https://meditechinsights.com/hemostats-market/request-sample/
Technological Advancements Drive the
Global Hemostats Market
Uncontrollable bleeding poses substantial fatality risks and
costs in the battlefield, emergency, and hospital settings. To address these
concerns, players operating in the market are focusing on developing hemostatic
agents that can rapidly control bleeding, possess antibacterial properties, can
be used as adjuncts to control bleeding during surgical procedures, and control
residual problematic bleeding if conventional methods fail.
- In
Feb 2022, Futura Surgicare Pvt Ltd.’s new vertical Dolphin Hemostats
launched hemostatic products under the brand Hemostax (Oxidised
Regenerated Cellulose). Hemostax Standard is an absorbable hemostat that
is designed to help surgeons control bleeding more efficiently.
- In
July, 2021, Medcura, Inc. launched a new class of high-performance,
antibacterial hemostatic gel, Rapid-Seal®. It provides rapid bleeding
management and antibacterial capabilities to improve wound treatment, help
fight infections of the wound and promote an environment for safe healing.
Plastic Surgery - An Untapped Market
Plastic surgery represents a commercially lucrative
opportunity for the hemostats market. Similar to most surgical procedures,
plastic surgery procedures are also not without associated complications.
Seromas and hematomas are relatively common complications associated with
plastic surgery procedures. These complications adversely impact wound healing
and result in substantial morbidity in patients. The use of hemostatic agents
can significantly reduce these complications, achieve immediate hemostasis for
the local bleeding site, allow earlier drain removal, and potentially avoid the
use of drains altogether.
“Technologically advanced products are likely to be
successful in the market. I think, there is only one product in the market that
has complementary characteristics of advanced bleeding control and
antimicrobial activity.” - Director, Leading Hemostat
Manufacturer, United States
Emerging Markets Set to Drive the Hemostatic Agents
Market
Emerging markets such as China, India, and South Korea are
expected to witness double-digit growth in the coming years. The growth in the
emerging markets is likely to be driven by lower-priced hemostatic products
that are largely commoditized. The huge volume of surgical procedures, rising
cases of trauma injuries, increasing cases of organ transplantation (legal
& illegal), foray of local players, and growing capabilities of surgeons to
undertake more complex and technically-challenging procedures that require
efficacious, fast-acting hemostats to control bleeding are some of the key
factors that are expected to fuel the demand of hemostatic agents in emerging
markets.
Organic and Inorganic Growth Strategies Adopted by
Players to Establish Their Foothold in Hemostats Market
The global hemostats market is marked by the presence of
both established and new players. Players operating in the market adopt both
organic and inorganic growth strategies such as new product launches, and
acquisitions to garner market share. For instance,
- In
July 2021, Baxter acquired PerClot Polysaccharide Hemostatic System from
CryoLife. The acquisition marks Baxter’s entry into the attractive global
hemostatic powder segment, broadening its portfolio offering to include a
wider range of active and passive hemostatic solutions.
- In
December 2020, Teleflex completed the acquisition of Z-Medica, LLC, an
industry-leading manufacturer of hemostatic products.
- In
March 2020, Ethicon, launched Surgicel® Powder Absorbable Hemostat in
Australia, New Zealand, and Thailand. The company has further plans of
launching it in Japan, Malaysia and India. Surgicel® Powder Absorbable
Hemostat is a powdered adjunctive hemostat that is designed to help
surgeons control disruptive bleeding more efficiently.
The global hemostats market is set to continue its growth
due to the rise in surgical procedure volumes, technological advancements in
hemostats, growing usage of hemostats in the military, emergency medical
services (EMS) & hospitals, and commercial opportunities in minimally
invasive surgery (MIS), plastic surgery, and knee replacement surgery.
Unlock key
findings! Fill out a quick inquiry to access a sample report
https://meditechinsights.com/hemostats-market/request-sample/
Competitive Landscape Analysis: Hemostats Market
The hemostats market is marked by the presence of key
players such as Baxter, Ethicon, B. Braun, Becton Dickinson, Pfizer, CryoLife,
Teleflex (Z-Medica), Integra LifeSciences, Biomup, Medtronic, among others.
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research
& insights firm. Our clients include Fortune 500 companies, blue-chip
investors & hyper-growth start-ups. We have completed 100+ projects in
Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma
Services in the areas of market assessments, due diligence, competitive
intelligence, market sizing and forecasting, pricing analysis &
go-to-market strategy. Our methodology includes rigorous secondary research combined
with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply
side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
Comments
Post a Comment